Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
study including 20 patients with NSCL stage IV. All patients received Erlotinib
150 mg / day continuously in second line setting after failure of platinum
based chemotherapy, associated with pemetrexed for non squamous cell
carcinoma and associated with gemcitabine for squamous cell carcinoma (scc).
Results: Twenty patients was included in the study; the average age was 60
years with male predominance (19 men and one woman), PS ranges from 0 to
3 ((50% has PS= 0-1, and 38% PS 2, 12 to 3%). Histological type predominant is
adenocarcinoma (60%) treated in first line with Cisplatine + Pemetrexed; 40%
squamous cell carcinoma type of cases treated with platine + Gemcitabine.
PFS was 5 months with 12 months of overall survival. The most common
side effects was: 50 % skin rash of the face (50%) with 10 % of grade III, 20
% of Diarrhea grade II.Conclusion: Erlotinib is well tolerated as second line
treatment of metastatic NSCLC with unknown EGFR status. This second line
treatment with erlotinib show an encouraging median survival and PFS in this
setting.
Keywords: second line treatment, EGFR unknow, NSCLC, Erlotinib
PUB089 TISSUE ENGINEERED CLINICAL AIRWAY RECONSTRUCTION
FOR LUNG CANCER TREATMENT
Qiang Tan 1 , Walter Weder 2 , Shun Lu 3 , Qingquan Luo 1
1 Shanghai Chest Hospital, Shanghai/China, 2 Division of Thoracic Surgery, University
Hospital Zurich, Zurich/Switzerland, 3 Shanghai Lung Cancer Center, Shanghai Chest
Hospital, Shanghai Jiao Tong University, Shanghai/China
Background: Delayed revascularization process and substitute infection
remain key challenges to tissue engineered TE airway reconstruction. We
advanced an “in-vivo bioreactor” design described as implanted TE substitutes
perfused with an intra-scaffold medium flow created by an extracorporeal
portable pump system for in situ regeneration. The perfusate will maintain
the survival of pre-seeded cells secreting revascularization growth factors
to accelerate revascularization process. Meanwhile antibiotic inside the
perfusate will control topical infection. Methods: One stage IIIA squamous
lung cancer patient received a 5cm TE airway substitute with in-vivo
bioreactor design to bridge left basal segment bronchus to carina avoiding left
pneumonectomy. Intra-scaffold continuous Ringer’s-Gentamicin perfusion
together with orthotopic peripheral total nuclear cells TNCs injection
twice a week lasted for one month. The perfusate waste were collected
very 4 hours for revascularization growth factors test. Results: The patient
recovered uneventfully. Bronchoscopy follow-up showed revascularization
and reepithelialization were confirmed four months postoperatively.
Perfusate waste test demonstrated various revascularization growth factors
secreted by TNCs. The patient received two cycles of chemotherapy and 30Gy
radiotherapy thereafter without complications related to the TE substitute.
Conclusion: In-vivo bioractor combines the traditionally separated in vitro 3D
cell-scaffold culture system and the in vivo regenerative processes associated
with TE substitutes, while treating the recipients as bioreactors for their TE
prostheses. This design is feasible to be used in clinic. We also proved for the
first time that TE airway substitute is able to tolerate chemo-radiotherapy
and suitable to be used in cancer treatment.
Keywords: tissue engineering, airway reconstruction, lung cancer surgery
PUB090 IDENTIFICATION OF A NOVEL APPROACH TO
PHOSPHORYLATE IRF3 AND ITS ENGAGEMENT TO INDUCE
APOPTOSIS VIA MDA5/RIG-I PATHWAY IN NON-SMALL CELL LUNG
CANCER
S790 Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017